You are here: Industry Insights > OS

News List

Survival Increase Seen for Adults With Relapsed Ph+ ALL drugs.com
January 18, 2022
Real-world data show steady improvement in overall survival (OS) for patients with Philadelphia-positive (Ph+) acute lymphoblastic...
MSD's Keytruda misses advanced bladder cancer goal pharmatimes
June 16, 2020
MSD's Keytruda (pembrolizumab) has failed to hit key goals in a trial assessing its potential as a first-line treatment for bladder cancer.
Imfinzi shows sustained OS benefit in first-line ES-SCLC in CASPIAN trial pharmaceutical-business-review
June 03, 2020
Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin ...
Public Insurance Tied to Lower Cancer Survival in Young Patients drugs
December 30, 2019
Young, low-income patients with bone or soft tissue sarcomas have decreased overall survival (OS), regardless of disease stage at presentation, according to a study published online December in Cancer Medicine.
Roche's first-line Tecentriq combo scores accelerated FDA review pharmafile
December 07, 2018
Roche’s immunotherapy Tecentriq has secured Priority Review from the FDA, the company has announced, in combination with carboplatin and etoposide (chemotherapy) for the first-line treatment of extensive-stage small cell lung cancer (ESCLC).